MedTrace Logo

First Line Ovarian Cancer Treatment - Cohort Study

NCT01832415 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-03-17

No results posted yet for this study

Summary

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Bevacizumab

Observation of bevacizumab administration in first line ovarian cancer treatment

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Dominique BERTON-RIGAUD, MD · ICO de l'Ouest, Site René Gauducheau - Saint-Herblain

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-02-28
Completion
2016-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01832415 on ClinicalTrials.gov